Episode 54
Biotech Hangout
00:00
Sonomaan and the Emerging Two: A Proof of Concept Study
We were thrilled with the data and it's really rare to see in a neuropsych study to see this consistency of results. After the first phase three read out, I guess it's the emergent two, which was kind of could have been the second phase three. They could have filed based on that. We started getting a lot of in-bounds around our royalty because we, in addition to equity, some of which we've monetized, we have the right to receive royalties as a co-inventor. If this ends up being a huge drug, we actually keep 67% of any revenue above two, you know, of the royalties on revenues above two billion. So
Transcript
Play full episode
